(03)4638800轉7904 aicenter@g.yzu.edu.tw

最新消息

AI浪潮來襲　元智大學培育智慧人才應戰

  • 2021-01-04

test_NeutraKine™系列抗體的主要優勢

NeutraKine™抗體使用真正的HumanKine®人類蛋白質作為免疫原，因此可以生產與天然形式的目標蛋白結合力更強的中和抗體。

嚴格把關並測試NeutraKine™抗體對HumanKine®蛋白活性的中和作用。

阻斷細胞激素風暴中過量產生的IL-6和TNF-α可能是解決COVID-19疾病惡化的一種方法。而Proteintech的NeutraKine™中和抗體可針對與COVID-19相關的細胞激素進行中和反應。NeutraKine™抗IL6和抗TNFα中和抗體（圖2和3）提供了無與倫比的特異性和敏感性。Proteintech還提供了許多其他NeutraKine™抗細胞激素的中和抗體，這些抗體可以進一步加速探索關於COVID-19的治療方法。

Figure 2. Recombinant HumanKine® IL-6 (HZ-1019) stimulates proliferation of hybridoma (Proteintech anti-GST clone 3G12B10) in a dose-dependent manner (blue curve, refer to the bottom X-axis and left Y-axis). The activity of human IL-6 (1 ng/mL HZ-1019) is neutralized by NeutraKine™ IL-6 antibody (69001-1-IG) at serial dilution (red curve, refer to the top X-axis and right Y-axis). The ND50 is typically 3-15ng/mL.

Blog post Image
References
  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
  2. Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
  3. https://www.ptglab.com/news/blog/neutralizing-antibodies-and-their-role-in-covid-19-research/
Back to Top